glp 1 anxiety reduction Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agent in psychiatric and neurodevelopmental conditions: evidence from a drug target Mendelian randomization | BMC Psychiatry How GLP-1 Weight-Loss Drugs Affect

A 2025 study found that tripling semaglutides dose to 7.2 mg led to roughly 19% weight loss over 72 weeks, compared to 16% at the standard dose, a meaningful gain, though with higher rates of side effects

Antioxidative nanomaterials and biomedical applications

While more research is needed, this is a promising finding, considering COVID-19s devastating acute and long-term effects on organ systems

If you are on your skin brightening and anti-aging journey, a Vitamin C serum is a must-have in your skincare

Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer

This knowledge allows them to make educated decisions about their treatment options